Cargando…

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

BACKGROUND AND AIM: Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialys...

Descripción completa

Detalles Bibliográficos
Autores principales: Laham, Gustavo, Martínez, Alfredo P., Rojas Gimenez, Wanda, Amaya, Lucas, Abib, Anabel, Echegoyen, Natalia, Díaz, Carlos, Lucero, Alicia, Martelli, Antonella, Videla, Cristina, Neukam, Karin, Di Lello, Federico Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510528/
https://www.ncbi.nlm.nih.gov/pubmed/36152219
http://dx.doi.org/10.1007/s40620-022-01446-2
_version_ 1784797455747907584
author Laham, Gustavo
Martínez, Alfredo P.
Rojas Gimenez, Wanda
Amaya, Lucas
Abib, Anabel
Echegoyen, Natalia
Díaz, Carlos
Lucero, Alicia
Martelli, Antonella
Videla, Cristina
Neukam, Karin
Di Lello, Federico Alejandro
author_facet Laham, Gustavo
Martínez, Alfredo P.
Rojas Gimenez, Wanda
Amaya, Lucas
Abib, Anabel
Echegoyen, Natalia
Díaz, Carlos
Lucero, Alicia
Martelli, Antonella
Videla, Cristina
Neukam, Karin
Di Lello, Federico Alejandro
author_sort Laham, Gustavo
collection PubMed
description BACKGROUND AND AIM: Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. METHODS: Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. RESULTS: One hundred seven participants were enrolled [n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. CONCLUSIONS: The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety in patients on chronic dialysis. These results could be useful for designing future vaccination strategies, especially aimed at this risk group. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9510528
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95105282022-09-26 Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients Laham, Gustavo Martínez, Alfredo P. Rojas Gimenez, Wanda Amaya, Lucas Abib, Anabel Echegoyen, Natalia Díaz, Carlos Lucero, Alicia Martelli, Antonella Videla, Cristina Neukam, Karin Di Lello, Federico Alejandro J Nephrol original Article BACKGROUND AND AIM: Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. METHODS: Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. RESULTS: One hundred seven participants were enrolled [n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. CONCLUSIONS: The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety in patients on chronic dialysis. These results could be useful for designing future vaccination strategies, especially aimed at this risk group. GRAPHICAL ABSTRACT: [Image: see text] Springer International Publishing 2022-09-24 2023 /pmc/articles/PMC9510528/ /pubmed/36152219 http://dx.doi.org/10.1007/s40620-022-01446-2 Text en © The Author(s) under exclusive licence to Italian Society of Nephrology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle original Article
Laham, Gustavo
Martínez, Alfredo P.
Rojas Gimenez, Wanda
Amaya, Lucas
Abib, Anabel
Echegoyen, Natalia
Díaz, Carlos
Lucero, Alicia
Martelli, Antonella
Videla, Cristina
Neukam, Karin
Di Lello, Federico Alejandro
Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title_full Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title_fullStr Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title_full_unstemmed Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title_short Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
title_sort assessment of the humoral response to the homologous gam-covid-vac (sputnik v) or heterologous sputnik v/mrna-1273 (moderna) vaccination against sars-cov-2 in dialysis patients
topic original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510528/
https://www.ncbi.nlm.nih.gov/pubmed/36152219
http://dx.doi.org/10.1007/s40620-022-01446-2
work_keys_str_mv AT lahamgustavo assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT martinezalfredop assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT rojasgimenezwanda assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT amayalucas assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT abibanabel assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT echegoyennatalia assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT diazcarlos assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT luceroalicia assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT martelliantonella assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT videlacristina assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT neukamkarin assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients
AT dilellofedericoalejandro assessmentofthehumoralresponsetothehomologousgamcovidvacsputnikvorheterologoussputnikvmrna1273modernavaccinationagainstsarscov2indialysispatients